Home / Health / Telehealth Weight Drugs: Overdoses Surge
Telehealth Weight Drugs: Overdoses Surge
3 Jun
Summary
- Telehealth weight loss drug errors have surged dramatically.
- Patients report severe side effects and hospitalizations.
- Concerns grow over inadequate patient screening online.
Telehealth companies prescribing weight loss medications are experiencing a significant rise in medication errors and adverse patient outcomes. One patient, Karleigh McClain, was hospitalized with severe vomiting after mistakenly receiving a dose nearly nine times the recommended initial amount of semaglutide. Such incidents are becoming more common as demand for GLP-1 drugs explodes, with millions using online platforms for healthcare needs.
Critics express concern that obtaining weight loss prescriptions online is often too easy, with some companies providing minimal follow-up care. Experts like Dr. Marc-Andre Cornier highlight the lack of clear criteria for evaluating appropriate patient care through telehealth. This environment has led to medication errors, including incorrect dosing and poor communication, with reports to the FDA’s monitoring system increasing significantly.
Pharmaceutical companies like Eli Lilly and Novo Nordisk are pursuing legal action against telehealth providers, citing patient safety risks from unapproved compounded drugs. The FDA has also issued warning letters to companies for making misleading claims about these medications. These regulatory actions and lawsuits underscore a lack of standardization and oversight in how weight loss drugs are prescribed and distributed online.
